Traduction de «have access to medicines » (Néerlandais → Français) :

However, it is also important for the population of these countries to have access to medicines of the same quality as those on the European market.
However, it is also important for the population of these countries to have access to medicines of the same quality as those on the European market.

“This effort builds on the ongoing work of many partners committed to improving the lives of the 1 billion people affected by NTDs, most of whom are among the world’s poorest. “At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.
“At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.

Access-to-medicine programs including medication for malaria and leprosy reach 80 million patients in 2009 with contributions valued at USD 1.5 billion, or 3% of sales
Les programmes d’accès aux médicaments, qui comprennent des traitements contre le paludisme et la lèpre ont touché 80 millions de malades en 2009 avec des contributions s’élevant à USD 1,5 milliard soit 3% des ventes

Treatments worth USD 1.5 billion were contributed through Novartis access-to-medicine programs in 2009, reaching 79.5 million patients in need.
En 2009, Novartis a fourni pour USD 1,5 milliard de traitements par l’intermédiaire de ses programmes d’accès aux médicaments qui ont atteint 79,5 millions de patients dans le besoin.

To promote the proper use of a medicine, all relevant parties need to have objective, appropriate, up-todate and readily accessible information.
To promote the proper use of a medicine, all relevant parties need to have objective, appropriate, up-todate and readily accessible information.

The FAMHP and the BUM department in particular ensures that all parties have access to such information, so that medicines can be used rationally and safely.
The FAMHP and the BUM department in particular ensures that all parties have access to such information, so that medicines can be used rationally and safely.

Thus the FAHMP inspectors in the Production & Distribution department have a duty to control the relevant industry (medicines and health products), the blood establishments, the cell and tissue banks, the wholesale trade of medicines and health products, the retail and hospital pharmacies and the stocks of medicines at the veterinarians.
Thus the FAHMP inspectors in the Production & Distribution department have a duty to control the relevant industry (medicines and health products), the blood establishments, the cell and tissue banks, the wholesale trade of medicines and health products, the retail and hospital pharmacies and the stocks of medicines at the veterinarians.

The latter has been designated as having expertise as an “Official Medicines Control Laboratory”, recognised by the FAMHP and the European Directorate for the Quality of Medicines (EDQM), for the monitoring of immunological products for veterinary use prior to marketing authorisation for the Belgian market.
The latter has been designated as having expertise as an “Official Medicines Control Laboratory”, recognised by the FAMHP and the European Directorate for the Quality of Medicines (EDQM), for the monitoring of immunological products for veterinary use prior to marketing authorisation for the Belgian market.

In this first “annual report”, we have chosen to describe the transition from the DG Medicinal Products of the FPS Public Health to an autonomous medicines agency and provide more details about a number of activities in 2007.
In this first “annual report”, we have chosen to describe the transition from the DG Medicinal Products of the FPS Public Health to an autonomous medicines agency and provide more details about a number of activities in 2007.

Some achievements and figures for Unit II in 2007 Rapid alerts relating to the quality of medicines The Rapid Alerts System or RAS network is an international network whose purpose is to circulate information as quickly as possible about batches of medicines that have been identified as nonconforming, which were produced in non-GMP conditions or which do not belong to the distribution circuit that complies with the GDP.
Some achievements and figures for Unit II in 2007 Rapid alerts relating to the quality of medicines The Rapid Alerts System or RAS network is an international network whose purpose is to circulate information as quickly as possible about batches of medicines that have been identified as nonconforming, which were produced in non-GMP conditions or which do not belong to the distribution circuit that complies with the GDP.